FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
KORU Medical Systems FCF Yield % Related Terms
KORU Medical Systems FCF Yield % Historical Data
* Premium members only.
The historical data trend for KORU Medical Systems's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, KORU Medical Systems's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
KORU Medical Systems FCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, KORU Medical Systems's FCF Yield % distribution charts can be found below:
* The bar in red indicates where KORU Medical Systems's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KORU Medical Systems (KRMD) has a FCF Yield % of 0.06 as of Jul. 08, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on KORU Medical Systems and its competitors. According to the industry distribution chart, KORU Medical Systems ranks #400 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 46.8%.
Is KORU Medical Systems' FCF Yield % too high?
KORU Medical Systems' current FCF Yield % is 0.06. Based on the distribution chart, KORU Medical Systems ranks #400 out of 855 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, KORU Medical Systems has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does KORU Medical Systems' FCF Yield % compare to EMBC and PDEX?
According to the Medical Devices & Instruments industry distribution chart, KORU Medical Systems ranks #400 out of 855 companies for FCF Yield %. This puts KORU Medical Systems in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Devices & Instruments company?
A good FCF Yield % depends on the Medical Devices & Instruments industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on KORU Medical Systems and its competitors. KORU Medical Systems's current FCF Yield % is 0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is KORU Medical Systems stock overvalued right now?
Based on GuruFocus' analysis, KORU Medical Systems (KRMD) is currently considered Fairly Valued. The stock's GF Value™ is $4.08, compared to a current price of $4.44 — trading 8.8% above its estimated fair value. The current FCF Yield % is 0.06. KORU Medical Systems' overall GF Score™ is 76/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For KORU Medical Systems (KRMD), the current FCF Yield % is 0.06 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is KORU Medical Systems (KRMD) Overvalued in 2026?
Based on GuruFocus' analysis, KORU Medical Systems stock appears to be overvalued.
The current stock price of $4.44 is trading 8.8% above its estimated GF Value™ of $4.08.
GuruFocus considers KORU Medical Systems to be Fairly Valued.
Key valuation signals for KRMD:
FCF Yield %: 0.06
GF Value™: $4.08 vs. price of $4.44 (8.8% above fair value)
No single metric tells the full story. See the KRMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.
76GF Score
Get the complete analysis for KRMD
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KRMD has been successfully added to your 
